Directly Induced Neuron Culture
Materials Required
Principle
Directly induced neuron culture converts somatic cells, most commonly fibroblasts, into induced neurons without passing through a pluripotent or neural progenitor stage; classic evidence shows that mouse fibroblasts can be converted by Ascl1, Brn2/Pou3f2, and Myt1l, human fibroblasts can be converted by defined neuronal transcription factors, and human fibroblasts can also be converted by miR-9/9-124 with neurogenic or subtype-specifying transcription factors[1][2][3][4]. The readout is acquisition of neuronal identity and function, assessed by neuronal morphology, neuronal markers such as Tuj1/βIII-tubulin, MAP2, synapsin, and subtype markers when relevant, together with functional assays such as action-potential firing, synaptic activity, and electrophysiology[1][2][3][4].
MCE has not independently verified the accuracy of these methods. They are for reference only.
Experimental Materials
• Use viable fibroblast cultures as the starting somatic cell source; published protocols and original studies used mouse embryonic or postnatal fibroblasts, human fetal or postnatal fibroblasts, and adult human dermal fibroblasts[1][2][5].
• Use gene-delivery reagents or vectors to express neuronal reprogramming factors; reported factor sets include Ascl1/Brn2/Myt1l, Ascl1 with NeuroD1 and other neuronal transcription factors for human conversion, miR-9/9-124 with NEUROD2, and miR-9/9-124 with CTIP2/BCL11B, DLX1, DLX2, and MYT1L for striatal medium-spiny-neuron-like conversion[1][2][3][4].
• Use neuronal culture medium after factor delivery; protocol papers report stepwise culture after reprogramming-factor expression and maturation for approximately 30 days in the microRNA-based striatal neuron protocol[5].
• Use antibodies against pan-neuronal markers such as Tuj1/βIII-tubulin and MAP2 to quantify neuronal conversion, and use synaptic or subtype markers such as synapsin, GABA, DARPP-32, and CTIP2 when the intended output is generic neurons or striatal medium-spiny-neuron-like cells[1][3][4][5].
• Use nuclear counterstaining and fluorescent reporter readouts when delivered vectors encode a reporter; the microRNA-mediated conversion study used a lentiviral vector expressing miR-9/9-124 with a fluorescent marker to identify infected cells[3].
• Use standard mammalian cell-culture equipment for fibroblast culture, viral/vector transduction, medium exchange, and long-term neuronal culture; use fluorescence microscopy or immunocytochemistry imaging to quantify marker-positive cells, and use patch-clamp electrophysiology or synaptic recording when functional validation is required[1][2][3][4][5].
• Use gene-delivery reagents or vectors to express neuronal reprogramming factors; reported factor sets include Ascl1/Brn2/Myt1l, Ascl1 with NeuroD1 and other neuronal transcription factors for human conversion, miR-9/9-124 with NEUROD2, and miR-9/9-124 with CTIP2/BCL11B, DLX1, DLX2, and MYT1L for striatal medium-spiny-neuron-like conversion[1][2][3][4].
• Use neuronal culture medium after factor delivery; protocol papers report stepwise culture after reprogramming-factor expression and maturation for approximately 30 days in the microRNA-based striatal neuron protocol[5].
• Use antibodies against pan-neuronal markers such as Tuj1/βIII-tubulin and MAP2 to quantify neuronal conversion, and use synaptic or subtype markers such as synapsin, GABA, DARPP-32, and CTIP2 when the intended output is generic neurons or striatal medium-spiny-neuron-like cells[1][3][4][5].
• Use nuclear counterstaining and fluorescent reporter readouts when delivered vectors encode a reporter; the microRNA-mediated conversion study used a lentiviral vector expressing miR-9/9-124 with a fluorescent marker to identify infected cells[3].
• Use standard mammalian cell-culture equipment for fibroblast culture, viral/vector transduction, medium exchange, and long-term neuronal culture; use fluorescence microscopy or immunocytochemistry imaging to quantify marker-positive cells, and use patch-clamp electrophysiology or synaptic recording when functional validation is required[1][2][3][4][5].
Experimental Procedure
• Prepare healthy fibroblast cultures before induction; published work used fibroblasts as the starting cell population and then introduced neuronal fate determinants rather than first generating iPSCs or neural progenitors[1][2][3][4].
• Prepare the selected reprogramming system according to the intended neuronal output: Ascl1/Brn2/Myt1l for classic generic induced neurons, human neuronal transcription-factor combinations for human iNs, miR-9/9-124 plus NEUROD2 for microRNA-driven neuronal conversion, or miR-9/9-124 plus CTIP2/BCL11B, DLX1, DLX2, and MYT1L for striatal medium-spiny-neuron-like cultures[1][2][3][4][5].
• Seed fibroblasts under standard adherent culture conditions, deliver the selected transcription-factor or microRNA-based reprogramming construct, and replace fibroblast-growth conditions with neuronal conversion and maturation culture conditions after factor delivery, because the cited studies induced neuronal fate by ectopic expression of neuronal regulators followed by neuronal culture and maturation[1][2][3][4][5].
• Maintain cultures through the reported conversion window; the microRNA-based striatal neuron protocol describes a 30-day stepwise conversion, while the Neuron study evaluated striatal marker acquisition after extended culture and functional maturation[4][5].
• Assess conversion by immunostaining for neuronal markers and by morphology, and validate functional maturation by electrophysiology when the experimental endpoint requires functional neurons rather than marker-positive neuron-like cells[1][2][3][4].
• Quantify conversion as the percentage of cells positive for neuronal markers among total cells or reporter-positive infected cells, and interpret successful conversion only when marker expression is supported by neuronal morphology and, where required, functional evidence such as action potentials or synaptic properties[1][2][3][4][5].
• Include fibroblast-only or non-neuronal-vector controls as negative controls, because the microRNA-mediated study reported undetectable MAP2 signal in fibroblasts infected with a non-specific microRNA control, and use factor-combination comparisons as internal controls when testing modified protocols[3][4].
• Prepare the selected reprogramming system according to the intended neuronal output: Ascl1/Brn2/Myt1l for classic generic induced neurons, human neuronal transcription-factor combinations for human iNs, miR-9/9-124 plus NEUROD2 for microRNA-driven neuronal conversion, or miR-9/9-124 plus CTIP2/BCL11B, DLX1, DLX2, and MYT1L for striatal medium-spiny-neuron-like cultures[1][2][3][4][5].
• Seed fibroblasts under standard adherent culture conditions, deliver the selected transcription-factor or microRNA-based reprogramming construct, and replace fibroblast-growth conditions with neuronal conversion and maturation culture conditions after factor delivery, because the cited studies induced neuronal fate by ectopic expression of neuronal regulators followed by neuronal culture and maturation[1][2][3][4][5].
• Maintain cultures through the reported conversion window; the microRNA-based striatal neuron protocol describes a 30-day stepwise conversion, while the Neuron study evaluated striatal marker acquisition after extended culture and functional maturation[4][5].
• Assess conversion by immunostaining for neuronal markers and by morphology, and validate functional maturation by electrophysiology when the experimental endpoint requires functional neurons rather than marker-positive neuron-like cells[1][2][3][4].
• Quantify conversion as the percentage of cells positive for neuronal markers among total cells or reporter-positive infected cells, and interpret successful conversion only when marker expression is supported by neuronal morphology and, where required, functional evidence such as action potentials or synaptic properties[1][2][3][4][5].
• Include fibroblast-only or non-neuronal-vector controls as negative controls, because the microRNA-mediated study reported undetectable MAP2 signal in fibroblasts infected with a non-specific microRNA control, and use factor-combination comparisons as internal controls when testing modified protocols[3][4].
Troubleshooting
Low neuronal marker-positive conversion:
Possible CauseReprogramming-factor combinations may be insufficient for the target human cell type or subtype.
Solution
Use factor combinations shown for the desired output, such as Ascl1/Brn2/Myt1l for classic iNs, miR-9/9-124 plus NEUROD2 for human fibroblast neuronal conversion, or miR-9/9-124 plus CTIP2/BCL11B, DLX1, DLX2, and MYT1L for striatal neuron-like conversion[1][3][4][5].
Marker-positive cells lack functional maturation:
Possible CauseNeuronal marker expression can precede mature electrophysiological properties.
Solution
Extend maturation and verify function by electrophysiology, because cited studies used action-potential firing, synaptic activity, or membrane properties to establish functional neuronal identity[1][2][3][4].
Subtype marker yield is low in striatal conversion:
Possible CauseGeneric neuronal conversion is not sufficient to impose striatal medium-spiny-neuron-like identity.
Solution
Combine miR-9/9-124 with striatal transcription factors CTIP2/BCL11B, DLX1, DLX2, and MYT1L, as this combination was reported to guide human fibroblasts toward striatal medium-spiny-neuron-like cells[4][5].
References:
- [1]. Vierbuchen T, et al. Direct conversion of fibroblasts to functional neurons by defined factors. Nature. 2010;463(7284):1035-1041. [Content Brief]
- [2]. Pang ZP, Yang N, Vierbuchen T, Ostermeier A, Fuentes DR, Yang TQ, et al. Induction of human neuronal cells by defined transcription factors. Nature. 2011;476(7359):220-223. [Content Brief]
- [3]. Yoo AS, Sun AX, Li L, Shcheglovitov A, Portmann T, Li Y, et al. MicroRNA-mediated conversion of human fibroblasts to neurons. Nature. 2011;476(7359):228-231. [Content Brief]
- [4]. Victor MB, Richner M, Hermanstyne TO, Ransdell JL, Sobieski C, Deng PY, et al. Generation of human striatal neurons by microRNA-dependent direct conversion of fibroblasts. Neuron. 2014;84(2):311-323. [Content Brief]
- [5]. Richner M, et al. MicroRNA-based conversion of human fibroblasts into striatal medium spiny neurons. Nat Protoc. 2015;10(10):1543-1555. [Content Brief]
LinkedIn
Researchgate
Instagram
X
Facebook
WhatsApp
Reddit
Mail